Corcept Therapeutics (CORT) soared nearly 20% on Wednesday, marking its biggest one-day gain in recent years. The sharp rally came after the company announced that the U.S. Food and Drug Administration (FDA) had approved its investigational drug Lifyorli in combination with nab-paclitaxel for the treatment of platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer in adult patients who have received one to three prior systemic regimens.
The approval, disclosed before the market opened, sent shares up 19.72% by the close, lifting the company’s market capitalization to approximately $4.5 billion. The strong investor response reflects growing confidence in the commercial potential of the newly approved therapy.
The approval was supported by data from the Rosella trial, a study involving 381 patients who received either the combination therapy or Lifyorli as a monotherapy. Results showed that the combination demonstrated clinically meaningful efficacy in patients with platinum-resistant ovarian cancer, according to the company.
While Corcept has long been known for its work in cortisol modulation, the approval marks a significant breakthrough in oncology, validating the broader applicability of its technology platform.
“Today’s approval of Lifyorli is an important first step, but there is much more to explore with this new mode of treatment,” said Joseph Belanoff, CEO of Corcept, signaling potential future expansions into additional tumor types or combination regimens.
Corcept’s revenue has historically been driven by its flagship product Korlym, approved for Cushing’s syndrome. In the third quarter, the company reported revenue of $207.6 million, up from $182.5 million a year earlier. Management reaffirmed full-year revenue guidance in the range of $800 million to $850 million. As of the end of the quarter, Corcept held $524 million in cash and investments, providing ample balance sheet flexibility.
With Korlym continuing to grow, the approval of Lifyorli represents a strategic expansion into oncology—specifically into platinum-resistant ovarian cancer, a segment with significant unmet medical need. Analysts view the new drug as a potential second growth engine that complements the company’s existing pipeline focused on cortisol modulation.
Beyond the near-term boost from the approval, investors are also responding to what the decision signals about Corcept’s broader R&D capabilities. The company is advancing multiple drug candidates targeting metabolic, oncologic, and neuropsychiatric disorders, and the regulatory win is expected to bolster confidence in its pipeline.
Still, while the approval removes a key overhang, execution risks remain, including commercial rollout, reimbursement, and competition from existing chemotherapy regimens. Nevertheless, with a strong balance sheet and a clear strategic focus, Corcept appears well-positioned for its next phase of growth. In the coming quarters, market attention will likely center on Lifyorli’s launch trajectory and further clinical developments in the company’s oncology pipeline.
